Gary Dahl

Clinical Focus

• Hematology/Oncology/Stem Cell Transplant, Pediatric
• Oncology (Cancer), Pediatric
• Pediatric Hematology-Oncology

Professional Education

• Board Certification: Pediatric Hematology-Oncology, American Board of Pediatrics (1976)
• Board Certification: Pediatrics, American Board of Pediatrics (1976)
• St. Jude Children's Research Hospital (1976) TN
• University of Oregon (1974) OR
• University of Oregon (1968) OR
• University of Oregon Medical School (1967) OR

Current Research Interests

Hematology/Oncology, Phase I drug studies for childhood cancer, overcoming multidrug resistance in leukemia and solid tumors, biology and treatment of acute nonlymphocytic leukemia, early detection of central nervous system leukemia by measuring growth, factor binding proteins.

Clinical Trials

• Clofarabine Plus Cytarabine Versus Conventional Induction Therapy And A Study Of NK Cell Transplantation In Newly Diagnosed Acute Myeloid Leukemia Recruiting
• Low-Dose Radiation Therapy and Combination Chemotherapy Following Surgery in Treating Children With Newly Diagnosed Primitive Neuroectodermal Tumor or Medulloblastoma Recruiting
• Rasburicase Treatment for Chemotherapy or Malignancy-Induced Hyperuricemia in Asthma/Allergy Patients No longer recruiting
• Repeat-Dose of Forodesine Hydrochloride (BCX-1777) Infusion in Patients With Advanced T-Cell Leukemia Completed
• Treatment of Patients With Newly Diagnosed Acute Myeloid Leukemia or Myelodysplasia No longer recruiting
• Lenalidomide in Treating Young Patients With Relapsed or Refractory Solid Tumors or Myelodysplastic Syndromes No longer recruiting
• Temozolomide, Vincristine, and Irinotecan in Treating Young Patients With Refractory Solid Tumors Completed
• Valproic Acid in Treating Young Patients With Recurrent or Refractory Solid Tumors or CNS Tumors Completed
• Vorinostat With or Without Isotretinoin in Treating Young Patients With Recurrent or Refractory Solid Tumors, Lymphoma, or Leukemia Completed
• hu14.18-Interleukin-2 Fusion Protein in Treating Young Patients With Recurrent or Refractory Neuroblastoma Completed

Publications

• Identification of a novel p53 in-frame deletion in a Li-Fraumeni-like family. Schiffman JD,  Chun N, Fisher PG, Dahl GV, Ford JM, Eggerding FA.  Pediatr Blood Cancer.  2008; 50 (4): 914-6
• Concerns about infertility risks among pediatric oncology patients and their parents. Oosterhuis BE,  Goodwin T, Kiernan M, Hudson MM, Dahl GV.  Pediatr Blood Cancer.  2008; 50 (1): 85-9
• Cardiomyopathy in children with Down syndrome treated for acute myeloid leukemia: a report from the Children's Oncology Group Study POG 9421. O'Brien MM,  Taub JW, Chang MN, Massey GV, Stine KC, Raimondi SC, Becton D, Ravindranath Y, Dahl GV.  J Clin Oncol.  2008; 26 (3): 414-20
• Reinduction of relapsed acute promyelocytic leukemia with ATRA and low dose antimetabolite-based chemotherapy. Dvorak CC,  Sanders RP, Dahl GV, Donaldson SS, Razzouk BI.  Pediatr Blood Cancer.  2007; 48 (5): 582-5
• Outcomes of transplantation in children with primary hepatic malignancy. Beaunoyer M,  Vanatta JM, Ogihara M, Strichartz D, Dahl G, Berquist WE, Castillo RO, Cox KL, Esquivel CO.  Pediatr Transplant.  2007; 11 (6): 655-60
• In cyclosporine-induced neurotoxicity, is tacrolimus an appropriate substitute or is it out of the frying pan and into the fire?-Response. Minn AY,  Fisher PG, Barnes PD, Dahl GV.  Pediatr Blood Cancer.  2007;
• Attitudes and practices of pediatric oncology providers regarding fertility issues. Goodwin T,  Elizabeth Oosterhuis B, Kiernan M, Hudson MM, Dahl GV.  Pediatr Blood Cancer.  2007; 48 (1): 80-5
• A syndrome of irreversible leukoencephalopathy following pediatric allogeneic bone marrow transplantation. Minn AY,  Fisher PG, Barnes PD, Dahl GV.  Pediatr Blood Cancer.  2007; 48 (2): 213-7
• CpG island methylator phenotype and childhood leukemia. Lacayo NJ,  DiMartino JF, Wei MC, Dahl GV.  Clin Cancer Res.  2006; 12 (16): 4787-9
• Anthracyclines cause endothelial injury in pediatric cancer patients: a pilot study. Chow AY,  Chin C, Dahl G, Rosenthal DN.  J Clin Oncol.  2006; 24 (6): 925-8
• Profile of daily life in children with brain tumors: an assessment of health-related quality of life. Bhat SR,  Goodwin TL, Burwinkle TM, Lansdale MF, Dahl GV, Huhn SL, Gibbs IC, Donaldson SS, Rosenblum RK, Varni JW, Fisher PG.  J Clin Oncol.  2005; 23 (24): 5493-500
• Gene expression profiles at diagnosis in de novo childhood AML patients identify FLT3 mutations with good clinical outcomes. Lacayo NJ,  Meshinchi S, Kinnunen P, Yu R, Wang Y, Stuber CM, Douglas L, Wahab R, Becton DL, Weinstein H, Chang MN, Willman CL, Radich JP, Tibshirani R, Ravindranath Y, Sikic BI, Dahl GV.  Blood.  2004; 104 (9): 2646-54
• Pharmacokinetic interactions of cyclosporine with etoposide and mitoxantrone in children with acute myeloid leukemia. Lacayo NJ,  Lum BL, Becton DL, Weinstein H, Ravindranath Y, Chang MN, Bomgaars L, Lauer SJ, Sikic BI, Dahl GV.  Leukemia.  2002; 16 (5): 920-7
• Surveillance neuroimaging to detect relapse in childhood brain tumors: a Pediatric Oncology Group study. Minn AY,  Pollock BH, Garzarella L, Dahl GV, Kun LE, Ducore JM, Shibata A, Kepner J, Fisher PG.  J Clin Oncol.  2001; 19 (21): 4135-40
• Modified cyclophosphamide, hydroxydaunorubicin, vincristine, and prednisone therapy for posttransplantation lymphoproliferative disease in pediatric patients undergoing solid organ transplantation. Suryanarayan K,  Natkunam Y, Berry G, Bangs CD, Cherry A, Dahl G.  J Pediatr Hematol Oncol.  2001; 23 (7): 452-5
• Mitoxantrone, etoposide, and cyclosporine therapy in pediatric patients with recurrent or refractory acute myeloid leukemia. Dahl GV,  Lacayo NJ, Brophy N, Dunussi-Joannopoulos K, Weinstein HJ, Chang M, Sikic BI, Arceci RJ.  J Clin Oncol.  2000; 18 (9): 1867-75
• Management of children with metastatic spinal myxopapillary ependymoma using craniospinal irradiation. Chinn DM,  Donaldson SS, Dahl GV, Wilson JD, Huhn SL, Fisher PG.  Med Pediatr Oncol.  2000; 35 (4): 443-5
• A multi-institutional retrospective study of intracranial ependymoma in children: identification of risk factors. Horn B,  Heideman R, Geyer R, Pollack I, Packer R, Goldwein J, Tomita T, Schomberg P, Ater J, Luchtman-Jones L, Rivlin K, Lamborn K, Prados M, Bollen A, Berger M, Dahl G, McNeil E, Patterson K, Shaw D, Kubalik M, Russo C.  J Pediatr Hematol Oncol.  1999 May-Jun; 21 (3): 203-11
• BCL-2 expression does not not correlate with patient outcome in pediatric acute myelogenous leukemia. Naumovski L,  Martinovsky G, Wong C, Chang M, Ravendranath Y, Weinstein H, Dahl G.  Leuk Res.  1998; 22 (1): 81-7
• Neoplastic disorders after pediatric heart transplantation. Bernstein D,  Baum D, Berry G, Dahl G, Weiss L, Starnes VA, Gamberg P, Stinson EB.  Circulation.  1993; 88 (5 Pt 2): II230-7